Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
https://doi.org/10.22416/1382-4376-2024-34-1-37-46
Abstract
Background. Some studies have shown that resveratrol may prevent, delay, or treat liver damage. This study aimed to provide up-to-date evidence regarding the effect of resveratrol on the liver enzymes (ALT & AST) in NAFLD patients. We conducted a systematic review and meta-analysis to evaluate the effect of resveratrol on liver enzymes in patients with NAFLD by searching various databases for published RCTs.
Methods. A systematic search in PubMed, Scopus, and Web of Science was performed up to September 2023. This systematic review and meta-analysis included all the RCT studies assessing resveratrol supplements on serum AST and/or ALT in NAFLD patients. The effect was presented as a mean difference and 95 % confidence interval (CI) in a random-effects model.
Results. Finally, six eligible randomized controlled trials consisting of 256 patients were found. Resveratrol had no significant effect on serum ALT (Mean diff = 3.30 IU/L; 95 % CI: –2.34, 8.94; p = 0.25) and AST (Mean diff = 0.07 IU/L; 95 % CI: –2.96, 3.10; p = 0.96) concentrations. Moreover, subgroup analysis revealed that neither resveratrol dose nor intervention duration had any significant effect on the serum ALT and AST levels.
Conclusion. The current evidence shows that resveratrol supplementation did not affect liver enzymes in NAFLD patients.
About the Authors
P. Ebrahimpour
Hamadan University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Pardis Ebrahimpour — Department of Nutrition and Food Hygiene, Student Research Committee
6517838636, Hamadan, Shaheed Fahmideh Ave
M. Karamian
Hamadan University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Mohammad Karamian — Department of Nutrition and Food Hygiene, Student Research Committee
6517838636, Hamadan, Shaheed Fahmideh Ave
A. Sharifi
Hamadan University of Medical Sciences
Islamic Republic of Iran
Islamic Republic of Iran
Amrollah Sharifi — Department of Nutrition and Food Hygiene, Nutrition Health Research Center
6517838636, Hamadan, Shaheed Fahmideh Ave
References
1. Darand M., Farrokhzad A., Ghavami A., Hadi A., Karimi E., Fadel A., et al. Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 2021;75(3):e13692. DOI: 10.1111/ijcp.13692
2. Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43. DOI: 10.1016/j.nutres.2014.09.005
3. Mojiri-Forushani H., Hemmati A., Khanzadeh A., Zahedi A. Effectiveness of grape seed extract in patients with nonalcoholic fatty liver: A randomized double-blind clinical study. Hepat Mon. 2022;22(1):e132309. DOI: 10.5812/hepatmon-132309
4. Elgebaly A., Radwan I.A., AboElnas M.M., Ibrahim H.H., Eltoomy M.F., Atta A.A., et al. Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis. J Gastrointestin Liver Dis. 2017;26(1):59–67. DOI: 10.15403/jgld.2014.1121.261.ely
5. Teng M.L., Ng C.H., Huang D.Q., Chan K.E., Tan D.J., Lim W.H., et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32–42. DOI: 10.3350/cmh.2022.0365
6. Wei S., Yu X. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Med. 2021;57:102635. DOI: 10.1016/j.ctim.2020.102635
7. Faghihzadeh F., Adibi P., Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796–803. DOI: 10.1017/S0007114515002433
8. Kantartzis K., Fritsche L., Bombrich M., Machann J., Schick F., Staiger H., et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20(7):1793–7. DOI: 10.1111/dom.13268
9. Teimouri M., Homayouni-Tabrizi M., Rajabian A., Amiri H., Hosseini H. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2022;70:102863. DOI: 10.1016/j.ctim.2022.102863
10. Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011;1812(11):1477–89. DOI: 10.1016/j.bbadis.2011.06.010
11. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–42. DOI: 10.1038/nature05354
12. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22. DOI: 10.1016/j.cell.2006.11.013
13. Chen S., Zhao X., Ran L., Wan J., Wang X., Qin Y., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 2015;47(3):226–32. DOI: 10.1016/j.dld.2014.11.015
14. Mahmood W.A., Mshimesh B.A.R., Khazaal F.A.K., Jasim S.Y., Mahmood A.A. Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Res. 2018;10(5):999–1005.
15. Asghari S., Asghari-Jafarabadi M., Somi M.H., Ghavami S.M., Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. J Am Coll Nutr. 2018;37(3):223– 33. DOI: 10.1080/07315724.2017.1392264
16. Heebøll S., Kreuzfeldt M., Hamilton-Dutoit S., Kjær Poulsen M., Stødkilde-Jørgensen H., Møller H.J., et al. Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51(4):456–64. DOI: 10.3109/00365521.2015.1107620
17. Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O'Moore-Sullivan T.M., Lee P., et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092– 103.e1–6. DOI: 10.1016/j.cgh.2014.02.024
18. Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2019.
19. Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. DOI: 10.1186/1471-2288-14-135
20. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17(1):1–12. DOI: 10.1016/0197-2456(95)00134-4
21. Farzin L., Asghari S., Rafraf M., Asghari-Jafarabadi M., Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res. 2020;90(3–4):279–89. DOI: 10.1024/0300-9831/a000528
22. Soltani S., Sharifi-Zahabi E., Sangsefidi Z.S., Ahmadi Vasmehjani A., Meshkini F., Clayton Z.S., et al. The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2023;37(3):1153–66. DOI: 10.1002/ptr.7719
23. Akbari M., Tamtaji O.R., Lankarani K.B., Tabrizi R., Dadgostar E., Haghighat N., et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19(1):25. DOI: 10.1186/s12944-020-1198-x
Review
For citations:
Ebrahimpour P., Karamian M., Sharifi A. Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):37-46. https://doi.org/10.22416/1382-4376-2024-34-1-37-46
Views:
2658
Email this article 
